BioCryst's Ebola drug shows promise in animal study

December 23, 2014 11:35 AM

3 0

The U.S. National Institutes of Health is funding the development of the intramuscular formulation of the drug, BCX4430, which is also being tested in an early-stage trial in healthy volunteers.

The main goal of the study was to assess the effectiveness of two doses of BCX4430, against a placebo, on survival through 41 days in Ebola-infected monkeys.

Read more

To category page